Dawn Cox
About Dawn Cox
Dawn Cox serves as the Lead of Pharmacovigilance Operations at Amylyx Pharmaceuticals, where she has implemented database reconciliation and continuous improvement initiatives for adverse event reporting. With a background in nursing and extensive experience in pharmacovigilance, she has held significant roles at UBC and Teva Pharmaceuticals.
Work at Amylyx Pharmaceuticals
Dawn Cox serves as the Lead of Pharmacovigilance Operations at Amylyx Pharmaceuticals, a position she has held since 2022. In this role, she is responsible for overseeing pharmacovigilance activities, ensuring compliance with regulatory requirements, and managing adverse event reporting processes. Her work includes implementing continuous improvement initiatives to enhance the efficiency of safety reporting and management on a global scale.
Previous Experience in Pharmacovigilance
Before joining Amylyx Pharmaceuticals, Dawn Cox worked as the Associate Director of Global Case Processing Pharmacovigilance at UBC from 2020 to 2022. In this capacity, she played a significant role in strategic planning and workflow development for pharmacovigilance operations. Her experience also includes a position at Teva Pharmaceuticals as a Call Center MS Nurse from 2009 to 2011, where she contributed to patient support and care.
Education and Expertise
Dawn Cox has a diverse educational background in nursing and health information management. She earned a Bachelor of Science in Nursing (BSN) from William Jewell College in 2006. Additionally, she obtained an Associate's degree in Health Information/Medical Records Administration from Texas State Technical College Harlingen in 1995. She also holds a Bachelor's degree in Computer and Information Sciences from DeVry University, completed in 2001.
Contributions to Pharmacovigilance Standards
In her roles, Dawn Cox has authored and reviewed pharmacovigilance standard operating procedures (SOPs) to ensure compliance and operational efficiency. She has collaborated with Regulatory Affairs to maintain and update regulatory reporting rules, ensuring the timely submission of expedited safety reports. Her efforts have contributed to the enhancement of adverse event reporting and management processes on a global scale.